Process Engineer/Scientist (Drug Product) - (Bothell, WA)

The Company Alder BioPharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on transforming the migraine treatment paradigm through the discovery, development and commercialization of novel therapeutic antibodies. Alder's lead product applicant, eptinezumab, is a pivotal-stage monoclonal antibody (mAb) that inhibits calcitonin gene-related peptide (CGRP). Eptinezumab is currently in late-stage clinical development and, if approved, will be the 1st-to-market infusion therapy for migraine prevention. Alder is also developing ALD1910, a preclinical mAb that inhibits pituitary adenylate cyclase-activating polypeptide-38 (PACAP-38) for migraine prevention. Alder expects to submit a Biologic Application License to the FDA for eptinezumab in early 2019. Alder plans to obtain regulatory approval in the United States for eptinezumab for the treatment of patients with episodic migraine and chronic migraine.